JP2021527699A5 - - Google Patents

Info

Publication number
JP2021527699A5
JP2021527699A5 JP2020571366A JP2020571366A JP2021527699A5 JP 2021527699 A5 JP2021527699 A5 JP 2021527699A5 JP 2020571366 A JP2020571366 A JP 2020571366A JP 2020571366 A JP2020571366 A JP 2020571366A JP 2021527699 A5 JP2021527699 A5 JP 2021527699A5
Authority
JP
Japan
Prior art keywords
composition according
gram
positive bacteria
lactam antibiotic
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020571366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527699A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/038525 external-priority patent/WO2019246552A1/en
Publication of JP2021527699A publication Critical patent/JP2021527699A/ja
Publication of JP2021527699A5 publication Critical patent/JP2021527699A5/ja
Pending legal-status Critical Current

Links

JP2020571366A 2018-06-22 2019-06-21 溶解素及びその誘導体がスタフィロコッカス・アウレウス及びグラム陽性細菌を抗生物質に再感作する Pending JP2021527699A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688756P 2018-06-22 2018-06-22
US62/688,756 2018-06-22
PCT/US2019/038525 WO2019246552A1 (en) 2018-06-22 2019-06-21 Lysins and derivatives thereof resensitize staphylococcus aureus and gram-positive bacteria to antibiotics

Publications (2)

Publication Number Publication Date
JP2021527699A JP2021527699A (ja) 2021-10-14
JP2021527699A5 true JP2021527699A5 (enExample) 2022-06-29

Family

ID=68983065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020571366A Pending JP2021527699A (ja) 2018-06-22 2019-06-21 溶解素及びその誘導体がスタフィロコッカス・アウレウス及びグラム陽性細菌を抗生物質に再感作する

Country Status (11)

Country Link
US (1) US20210260070A1 (enExample)
EP (1) EP3809851A4 (enExample)
JP (1) JP2021527699A (enExample)
KR (1) KR20210024005A (enExample)
CN (2) CN116850269A (enExample)
AU (1) AU2019288723A1 (enExample)
BR (1) BR112020026267A2 (enExample)
CA (1) CA3104650A1 (enExample)
IL (1) IL279596A (enExample)
MX (1) MX2020013935A (enExample)
WO (1) WO2019246552A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220193186A1 (en) * 2019-04-11 2022-06-23 Contrafect Corporation Method of treating and preventing bone and joint infections
US20220087266A1 (en) * 2020-09-22 2022-03-24 Mars, Incorporated Compositions and methods for controlling mycotoxin production
WO2022261360A1 (en) * 2021-06-09 2022-12-15 Contrafect Corporation Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria
MX2023014940A (es) * 2021-06-15 2024-02-16 Ferring Bv Bacteriofagos contra enterococci resistentes a la vancomicina.
CN120513297A (zh) * 2023-01-09 2025-08-19 华中农业大学 细菌裂解酶及其应用
CN117866985B (zh) * 2023-10-11 2024-08-30 圆因(北京)生物科技有限公司 一种用于表达耐甲氧西林金黄色葡萄球菌内溶素的rna序列

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2103308A1 (de) * 2008-03-20 2009-09-23 PhytoLine GmbH Verfahren zur Herstellung eines Gemisches von Bakteriophagen und deren Verwendung für die Therapie von Antibiotika-resistenten Staphylococcen
CA2729160C (en) * 2008-07-03 2017-11-14 The Rockefeller University A chimeric bacteriophage lysin with activity against staphylococci bacteria
AR073917A1 (es) * 2008-10-23 2010-12-09 Novozymes Adenium Biotech As Sinergismo antibiotico
MX389127B (es) * 2012-05-09 2025-03-19 Contrafect Corp Lisina de bacteriófago y combinaciones de antibióticos contra bacterias gram positivas.
EP3349780B1 (en) * 2015-09-17 2022-11-09 Contrafect Corporation Lysin polypeptides active against gram-negative bacteria

Similar Documents

Publication Publication Date Title
ter Boo et al. Antimicrobial delivery systems for local infection prophylaxis in orthopedic-and trauma surgery
JP2022163214A5 (enExample)
AU2019222918B2 (en) Antimicrobial peptides and methods of use thereof
Trampuz et al. Antimicrobial agents in orthopaedic surgery: prophylaxis and treatment
RU2020133461A (ru) Предотвращение, разрушение и обработка биопленки лизином бактериофага
RU2363489C2 (ru) Способ применения антибиотиков
ES2436614T3 (es) Composiciones y procedimientos de tratamiento de bacterias
WO2017049242A2 (en) Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
Kiran et al. Suppression of biofilm related, device-associated infections by staphylococcal quorum sensing inhibitors
RU2017102306A (ru) Лизины ацинетобактеров
HUP0002662A2 (hu) Lizosztafint magában vagy antibiotikus kombinációban tartalmazó gyógyászati készítmény, amely stafilokokkusz fertőzések kezelésére alkalmazható
JP2017526627A5 (enExample)
JP2012501349A5 (enExample)
IL275795B2 (en) Medical bacteriophage preparations for the treatment of staphylococcal infection
US20210260070A1 (en) Lysin cf-301 resensitizes methicillin-resistant staphylococcus aureua (mrsa) to penicillin derivatives and first generation cephalosporins
UA129222C2 (uk) Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою
RU2014133530A (ru) Синтетические пептиды для лечения бактериальных инфекций
US20110034557A1 (en) Antimicrobial compositions and uses thereof
RU2020142378A (ru) Ресенсибилизация staphylococcus aureus и грамположительных бактерий к антибиотикам лизинами и их производными
Sedarat et al. A Consideration of antibacterial agent efficacies in the treatment and prevention of formation of Staphylococcus aureus biofilm
JP2022525914A5 (enExample)
JP2022526624A5 (enExample)
CN108272792A (zh) 一种抑制耐甲氧西林金黄色葡萄球菌生物被膜的组合物
JP2023513934A5 (enExample)
De Gaudio et al. What is the role of streptogramins in intensive care?